Value in Health

Article	Citations
Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness	445
PCN185 Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada	433
Table of Contents	83
Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study	71
Instructions for Authors	71
Editorial Board	71
Developing an Australian Value Set for the Recovering Quality of Life-Utility Index Instrument Using Discrete Choice Experiment With Duration	67
Editorial Board	64
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases	64
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force	63
Economic Considerations in Designs and Modifications of Multiarm, Multistage Adaptive and Adaptive Platform Randomized Controlled Trials: A Systematic Literature Review	58
PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.	49
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England	47
Do Machine Learning Approaches Perform Better Than Regression Models in Mapping Studies? A Systematic Review	46
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review	45
EE313 Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar	44
Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study	44
POSB4 Effectiveness of Caplacizumab on Reducing Acute Mortality in Acquired Thrombotic Thrombocytopenic Purpura: Results from a French National Registry (CNR-MAT)	43
Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study	41
PIT1 Negative Pressure Wound Therapy for Pressure Ulcer: Effect on Outcomes and Utilization Using Real-World DATA	41
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact	39
Influence of Self-Reported Health Impairments on German EQ-5D-5L Values	38
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	38
PCR288 Input Parameters for Value-Based Alternative Payment Models in Expensive Drugs in the Western World: A Review and Use Case Study in the Netherlands	37
PCR190 The Value of Progression-Free Survival From the Perspectives of Patients With Multiple Myeloma and Treating Physicians: Qualitative Research Findings From Eight Countries	36

PCR292 Examining the Predictors of Patient-Level Variation in Self-Reported Health-Related Quality of Life (HRQOL) Among Inflammatory Bowel Disease in Ireland	35
PCR191 Counting on Data Validity in Multinational Clinical Trials? Numeral Systems in Patient-Reported Outcome Assessments: Guidance for Linguistic Validation	34
PCR192 Quality of Life and Its Drivers for Patients Living With Angelman Syndrome (AS): A Systematic Review	34
RWD85 Streamlining SNDS Data for RWE Studies: Victoria an Efficient Transformation Pipeline	34
PCR238 The Current Landscape of Patient Preference Studies: Are We Ready for Meta-Analyses and Benefit Transfers?	33
PCR201 Attitude Towards HPV Vaccination Among Mothers of 11-14 Year-Old Children	32
PCR202 Uncovering Preference and Scale Heterogeneity in Digital Neurorehabilitation: Results From a Discrete Choice Experiment	31
PCR214 Evaluating Patient Perceptions and Preferences of Biosimilars in South Korea	31
PCR240 Design and Validation of a Specific Clinical Outcome Measure for Adolescent Andadult Patients With Spinal Muscular Atrophy: An Interim Rasch Analysis	30
PCR241 Targeted Literature Review of in-Trial/Exit Interviews in Clinical Trials Focusing on Multiple Myeloma and Related Conditions	29
PCR178 Health-Related Quality of Life Among Individuals With Asthma in the United States	29
PCR233 Impact of Patient Recall and Reporting Intervals on Real-World Attack Reductions After Berotralstat Initiation in Hereditary Angioedema Patients Without C1-Inhibitor Deficiency	29
PCR278 Treatment Preferences of Patients With Ulcerative Colitis in Greece: A Cross-Sectional Patient Survey	29
PCR276 Learnings and Insights From the Implementation of Patient Reported Measures Dashboards to Support Usual Clinical Practice	28
EE515 Cost-Effectiveness Analysis of Sacubitril/Valsartan in Heart Failure Patients in Egypt	28
RWD156 Patterns of Co-Medications Among People With Schizophrenia in Hong Kong	28
EE435 The Economic Impact of Adopting a 4MM Pen Needle and Structured Education for Insulin Administration by Patients With Diabetes in Spain	28
EE214 Remote Monitoring As a Digital Health Intervention in the Management of Heart Failure in the United Kingdom: A Cost-Effectiveness Analysis	27
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis	27
HPR14 Lessons From History: Gauging Part D Plan Access Restrictions of Protected Class Drugs as a Harbinger for Coverage of Negotiated Drugs	27
EE476 Cost-Minimization and Budget Impact Analysis of Abiraterone (Tarosyn® and Avitosyn®) as Second Line Treatment for Metastatic Prostate Cancer Resistant to Castration in Mexico	27
CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials	27
EE112 Baricitinib in Alopecia Areata: A Budget Impact Analysis in Saudi Setting	26
HSD81 Impact of Specialty Pharmacy: A Study in Inflammatory Conditions	26
EE316 Economic Burden of Fabry Disease in Colombia	25
EPH149 Regional Dynamics and Prevalence of COVID-19 Variants in US Health and Human Services Regions	25
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China	25
EE189 A Budget Impact Analysis of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes Being Treated with Standard of Care in Tertiary Hospital, Riyadh, Saudi Arabia	24
CO81 Cyclosporine Ophthalmic Solution 0.09% Improves the Signs and Symptoms of Dry Eye Disease in Patients Whose Disease Is Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%	24
EE438 A Budget Impact Model (BIM) for the Introduction of the TEARCARE® System to a United States (US) Health Plan for the Treatment of Meibomian Gland Dysfunction (MGD)-Associated Dry Eye Disease (DE	23
EE390 Economic Evaluation and Healthcare Resource Utilization (HCRU) Among Breast Cancer Patients Treated with Palbociclib: A Systematic Literature Review (SLR)	23
EE352 Economic Burden of Prostate Cancer in the US: A Disease Stage-Based Cost Analysis	23
HTA43 Alignment Between Health Technology Assessment (HTA) Requirements and Current Practices in Global Value Dossier (GVD) Development	23
EE170 Social and Clinical Factors Influencing ED Utilization Behavior Amongst Blue Cross Blue Shield of Louisiana Members: A Cluster Analysis	23
EE122 Analyses of Cancer Prevalence and Healthcare Costs for Metastatic and Non-Metastatic Cancers Among Employees Using Claims Data	23
EE271 Lifetime Productivity Loss Due to HIV Mortality in the United States	23
EE141 Cost-Effectiveness of Pembrolizumab for Adjuvant Treatment of Patients With Renal-Cell Carcinoma Who Have Undergone Nephrectomy in Colombia	22
EPH60 Real-World Treatment Patterns in Adults with Pemphigus Vulgaris in the United States	22
EPH25 Maternal Sexually Transmitted Infection Trends and Characteristics in the United States: 2018-2022	22
EPH66 Pre-Exposure Prophylaxis Adherence Trajectories and HIV and Sexually Transmitted Infections Risk	22
CO67 Network Meta-Analysis to Compare the Efficacy Between Different Classes of PCSK9 Inhibitors, siRNA Vs. PCSK9 mAb, in Asian Patients With Hypercholesterolemia at Increased Cardiovascular Risk	22
EE387 Healthcare Resource Utilization for Patients With Alzheimer's Disease Versus Non-Alzheimer's Disease Controls in Israel	21
HTA13 Survey Data in Value Demonstration: Acceptability within Health Technology Assessments in the UK	21
EPH126 A Systematic Review of the Application of Health Behavioral Theories in Drug Disposal and Reuse	21
HSD33 Contraceptive Use Among Female Patients Who Underwent Bariatric Surgery in the U.S. Commercial Insurance Plans	21
RWD25 Trends and Utilization of Open, Laparoscopic, and Robotic-Assisted Appendectomy: A Retrospective Database Study	21
EPH196 A Claims-Based Analysis of Weight Management in Pediatric Populations Covered By Commercial or Medicaid Insurance	20
EE20 Cost Saving Analysis of Implementing Subcutaneous Formulation of Atezolizumab in a Danish Context (CS-ASSIST)	20
PCR42 Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Longitudinal Study Using the EQ5D and Health Utilities Index (HUI)	19
P51 Characterization of Misdiagnosed Opsoclonus Myoclonus Ataxia Syndrome (OMAS)	19

EE454 Economic Burden of Mild and Moderate Asthma in Adult Patients From Public Health Institutions Perspective in Mexico	19
EE207 Prevalence and Economic Burden for Diabetic Multimorbid Patients in China: Based on Longitudinal Claims Data	19
EE444 Target Trial Emulation with Real-World Data to Determine the Population-Level Cost-Effectiveness of Multi-Gene Panel Sequencing for Advanced Melanoma	18
RWD60 Evaluating Trends in the Use of RWE in FDA New Drug Approvals	18
RWD43 The Use of Code Llama, a Large Language Model, as Programming Assistant in Real-World Research	18
CO69 Burden of Clinical Syndromes Associated with Pneumococcal Disease in Ecuador: A 2019 Perspective	18
HTA7 Access to Pan-Tumor Therapies in Oncology – Do US Patients Have an Advantage?	18
CO137 Are Standard Indirect Treatment Comparison Methods Suitable to Compare First-Line Vs Maintenance Therapies? An Assessment of Enfortumab Vedotin + Pembrolizumab Vs Avelumab in Locally Advanced/Me	18
EPH134 Difference in E-Cigarette Use Prevalence in Adolescents between 2019 and 2021 in Georgia, United States	18
RWD59 Determinants of Smoking Cessation Program Completion and Continued Tobacco Use in a Referral Program: An EHR Data Analyses From 2018-2023	18
RWD130 European Health Data Space (EHDS) Requires Secure Processing Environments (SPEs) – Comparison of SPESiOR to Other SPE-Type Environments from Finnish, Nordic, European, and Global Settings	17
CO34 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists - Efficacy, Safety, and Cost-Effectiveness in Obesity Management: A Systematic Review	17
HSD42 Performance Assessment of a Disease-Agnostic Treatment Sequencing Heuristic for Deriving Line of Therapy (LOT) in a Real-World, Rare, Multi-Tumor Cohort across Tumor Mutational Burden (TMB) Stat	17
P35 Are Proposals for a Scheme to Stimulate Investment in Critically Needed New Antimicrobials Fit for Purpose?	17
RWD76 Prognosis of Myelodysplastic Syndrome Using De-Identified Market Clarity Database	17
CO43 A Systematic Literature Review of Comparative Efficacy Measures in Randomized Controlled Trials of Darolutamide Treatment in Metastatic Hormone-Sensitive Prostate Cancer	17
SA8 Methodological Approaches to Compare Treatment Options for Chronic Hepatitis D: An Early Network Meta-Analysis	16
CO49 Progression of Chronic Kidney Disease Among Older Adults with Hypertension Using Group-Based Trajectory Modeling	16
EE391 Cost-Effectiveness of Radar: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada	16
EE217 Budget Impact of RSVpreF Maternal Vaccine Among Pregnant Women for Prevention of Respiratory Syncytial Virus Among Privately Insured Infants in Dubai, UAE	16
SA19 Mapping the Current Clinical Landscape for Alzheimer's Disease: A Qualitative Analysis	16
HSD34 Analysis of Changes in the Number of Cases of Gynecological Surgeries for Benign Indications in Hungary	16
EPH61 Timing of SGLT2 Inhibitor Initiation and Hospital Readmission in Acute Heart Failure With Type 2 Diabetes: A Target Trial Emulation Cohort Study	16
HSD30 Incidence of Platinum-Resistant, Stage III/IV Ovarian Cancer Patients in the US: A Mixed Source Estimation Approach	16
P18 Assessing the Value of Revascularization Strategies for Chronic Limb Threatening Ischemia in Patients with Diabetic Foot Ulcers: A Propensity Score-Weighted Evaluation	16
EE142 A Cost Utility Analysis of Zuranolone in the Treatment of Major Depressive Disorder	16
EE275 Cost-Effectiveness Analysis of Biologics Used for the Treatment of Ankylosing Spondylitis in China	16
EE172 Quantifying the Relationship between Time to Diagnosis and Potential System Level Burden in Obstructive Hypertrophic Cardiomyopathy (HCM)	16
EPH16 Changes in Neutropenia Outcomes Following Implementation of the Clozapine Risk Evaluation and Mitigation Strategy Update	16
EE290 Targeted Literature Review of Cost-Effectiveness Models in Relapsed/Refractory Follicular Lymphoma	16
SA24 CHIME2 (Chinese Hong Kong Integrated Modeling and Evaluation): An Updated Model to Simulate Lifetime Health Outcomes of Patients with Type 2 Diabetes	16
P20 Cardioprotective Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Early Breast Cancer Following Anthracycline- or Trastuzumab-Based Chemotherapy	15
PCR38 Health-Related Quality of Life Associated with Generalized Anxiety Disorder Among Adults in the United States	15
MSR51 Evaluation of Machine Learning Approaches in Predicting the Initial Treatment Strategy in Patients with Multiple Sclerosis	15
HSD99 Impact of Pink October in Mammographic Screening in a Health Care Plan in Brazil	15
P22 Measuring Health-Related Quality of Life during Pregnancy: Exploring the Psychometric Properties of PROMIS to Assess Health-Related Quality of Life	15
P63 Comparative Analysis of Health Technology Assessment Agency Frameworks for Digital Health Technologies	15
EE151 Clinical and Economic Benefits of Adjuvanted and High-Dose Influenza Vaccines in the Elderly in Argentina	15
P11 Beyond Accuracy: Fairness Implications in High-Cost User Prediction Models Among Incident Lung Cancer Survivors	15
OP1 Assessing the Quality and Impact of Patient Engagement: Co-Creation of the Patient Engagement Impact Measurement (PEIM) Framework and Metrics	15
PCR34 Higher Patient Activation Levels May Mitigate Alzheimer’s Caregiving Burden	15
EE364 Cost-Effectiveness of Artificial-Intelligence Enabled Kidney Disease Risk Stratification in US Veterans With Early-Stage Diabetic Kidney Disease	15
HSD25 Patients’ Rare Disease Diagnoses and Their Impact on Physicians’ Emotions: A Cross-Sectional Study in the United States	15
EE199 Budget Impact Analysis of the Anti-Vegfs Injections for Treating Diabetic Macular Oedema: Assessing Their Affordability in the UK Healthcare System	14
RWD20 Enhancing Oncology Model: Discordance Among Patients Using Intravenous Iron in the US	14
CO1 The Rate of Ward to Intensive Care Transfer and Its Predictors Among Hospitalized COPD Patients: A Retrospective Study in a Local Tertiary Center in Saudi Arabia	14
EE365 Empowering Access: Evaluating the Impact of Partnerships for Productive Development (PDP) on Access to Rituximab in Brazil	14
MSR45 Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients With Atrial Fibrillation and Cancer	14
PCR46 A Qualitative Exploration of Patient and Healthcare Provider Perspectives on Oxybate Treatments for Narcolepsy	14
EE379 Assessing Trends in the Distribution of Prescription Claim Payments (2011-2021) and Implications for Retail Pharmacies	14
HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)	14
CO72 Investigating Regional Differences in Cardiovascular Outcomes Among Patients Diagnosed with Hypertrophic Cardiomyopathy	14
EPH65 Burden of Illness of Osteogenesis Imperfecta in Ontario, Canada	14
EPH87 Invasive Meningococcal Disease Risk Factors in Individuals With Commercial and Medicare Insurance in the United States	13
MT14 Assessing the Association Between Cardiovascular Acoustic Biomarkers and Heart Failure: A Systematic Literature Review	13
EPH115 Sex Differences on Limitations in Physical Functioning and Overall Quality of Life of People Living with Myasthenia Gravis from the MGFA Global MG Patient Registry (MGFAPR) in the US	13
EE419 The Economic Burden of Thyroid Eye Disease in the Kingdom of Saudi Arabia	13
EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population	13
HPR86 The Impact of Mandated Prescription Drug Monitoring Program Registration on Prescription Opioid-Related Mortality in California	13
EE388 Economic Evaluation and Budget Impact of Brigatinib Versus Other ALK-Inhibitors for First-Line ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Treatment in the Brazilian Private Healthcare Syste	13
EE45 Influential Factors on the Economic Justifiable Price: Systematic Investigation of Factors and Mechanisms Beyond the Incremental Cost Effectiveness Ratio	13
P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States	13
EE357 Using a Computer Vision-Based System for Reading Skin Prick Test Results: A Cost-Minimisation Analysis	13
EE358 Systematic Literature Review of Cost-Effectiveness Analyses of Adult 15- and 20-Valent Pneumococcal Vaccines	13
EE393 Assessing Cost-Effectiveness in Diabetes Management: A US Healthcare Payer’s Perspective on 15MG Tirzepatide Versus 1MG Semaglutide	13
EE215 Cost-Effectiveness Analysis of Turoctocog Alfa Pegol in Patients With Hemophilia A Without Inhibitors in Colombia	13
EE194 Health Care Resource Utilization, Total and out of Pocket Expenditures Among Adults with Rheumatoid Arthritis: Medical Expenditure Panel Survey Study	12
EE456 The Cost of Reusable Cystoscopy: A Microcosting Evaluation at a U.S. Academic Medical Center	12
EE195 The Cost of Missing Physiotherapy Appointments	12
RWD118 Implementation and Validation of a Prioritization Logic to Identify the Best Available Race/Ethnicity Information for Members in Commercial Plans	12
RWD126 Evaluation of the Importance of One-Day Surgical Treatment in Benign Gynecological Surgeries	12
HTA14 Payer Perspectives on the Use of ICER Evidence Reports Over the Past 24 Months	12
EE110 Leading Predictors of Medicare Payments Vary Across Different Phases of Care Among Older Hodgkin's Lymphoma Survivors: Application of Interpretable Machine Learning Models	12
EE407 Treatment Patterns and Healthcare Resource Utilization in Ruxolitinib-Treated Patients with Myelofibrosis with and without Anemia: A Real-World Analysis	12
CO93 Impact of Caring for Persons with Schizophrenia: Review of Burden Assessment Measures	12
EPH79 HPV-Associated Cancers in Men: Epidemiological and Economic Burden in Costa Rica	12
HTA16 A Preliminary Assessment of ICER's New HTA Methods That Support Health Equity	12
RWD135 Right-Sided vs Left-Sided Colorectal Cancer Hospitalization Outcomes in the US	12
EE181 Impact of Type 1 Diabetes on Productivity and Out-of-Pocket Costs of Adult Continuous Glucose Monitoring Users in the United States: Results From a Cross-Sectional Survey in the United States	12
EPH123 Incorporating Social Determinants of Health Into Transmission Modeling of COVID-19 Vaccine in the US: A Scoping Review	12

CO85 Longitudinal Patterns of Loss of Independence in Parkinson Disease	12
CO125 Disease Burden of Epithelial Ovarian Cancer in Chinese Patients Under Current Care: A Model Simulation Study	12
EE466 Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle-Cell Disease: A Case Study	12
CO126 Competing Risks of Death in Older Adults With Advanced Non-Small Cell Lung Cancer Receiving Programmed Cell Death Protein 1 (PD-1) Inhibitors	12
RWD34 Examining Bias in the Narxcare Score: Unveiling Disparities in AI/ML Features for Opioid Prescribing Decisions	12
EPH14 Association between the Use of Macrolide Antibiotics and Recurrent Wheezing in Hospitalized Infants with Bronchiolitis	11
EPH156 Multimorbidity and Its Associations with Adverse Cardiovascular Events and Healthcare Costs Among Patients with Atherosclerotic Cardiovascular Disease: A Real-World Evidence Study	11
HTA44 Systematic Literature Review Requirements for Health Technology Assessment in European Markets	11
EPH27 The Efficacy of Interventions Utilized in Communicating Risk Information to Improve Behavioral Outcomes Among Individuals Who Are Genetically Predisposed of Type 2 Diabetes: A Systematic Review	11
EE446 Economic Burden of Mild or Moderate Asthma in Pediatric Patients from the Perspective of Public Health Institutions in Mexico	11
CO163 Impact of Glucocorticoid Use on Mortality in Adults with Chronic Diseases: A Systematic Literature Review	11
EPH190 Trends and Disparities in Perinatal Health Outcomes Among Women from Refugee Backgrounds in Victoria, Australia: A Population-Based Study	11
EPH119 Public Health Results in the Department of Bolívar, Colombia: An Analysis of Indicators in 2023	11
CO153 Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma From Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)	11
CO139 Comparative Effectiveness of Rapid Vs. Non-Rapid Start of Anti-Retroviral Therapy in Patients With Human Immunodeficiency Virus Infection on Clinical Outcomes: A Systematic Literature Review and	11
EPH20 Trends in New Prescriptions for Opioids, Non-Opioids, and Opioid Antagonists in the United States, 2019 - 2023	11
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?	10
EE231 Use of Biomarkers in Health Care: What Health Economic Methods Are Used to Evaluate Them?	10
HTA40 Nirmatrelvir/Ritonavir for Non-Hospitalized Adults With Mild/Moderately Severe COVID-19: A Systematic Evidence Review of Randomized Controlled Trials and Real-World Studies With Meta-Analysis an	10
EPH176 Comparison of Superoxide Dismutase Activities (Mn-SOD AND Cu/Zn-SOD) in Patients Infected with Dengue Virus or Zika Virus	10
EPH175 Assessment of Streptococcus Pneumoniae as Cause of Acute Otitis Media in Young Children in Colombia: A Prospective Study	10
EE190 Association of Total Annual Costs of Duchenne Muscular Dystrophy With Disease Severity	10
POSC131 Events Avoided and Cost Savings Associated with the Use of Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients Stabilized after an Acute Heart Failure Episode wi	10
One-Year Costs Associated With the Veterans Affairs National TeleStroke Program	10
EE29 Cost-Effectiveness of Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer	10
EE258 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for High-Risk Patients in Chile	10
PCR145 A Qualitative Exploratory Study on Developing and Selecting Potential Bolt-on for the EQ-5D Hong Kong Sar, China	10
MSR30 Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab Japanese-Korean Clinical Trials for Migraine Prevention	10
EE153 Budget Impact Analysis of Introducing Mobocertinib for Locally Advanced or Metastatic Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small-Cell Lung Cancer in the United States	10
EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China	10
CO91 Systemic Therapy Eligibility Criteria of the International Psoriasis Council (IPC) May Reduce Undertreatment of PsO Patients with Low Body Surface Area Involvement Associated with High Disease Bu	10
EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the	10
EE263 Characterization of End-Stage Kidney Disease Patients With and Without Autosomal Dominant Polycystic Kidney Disease and Receiving Kidney Transplantation in the United States	10
EE270 Cost-Utility Analysis of Add-on Stiripentol Vs Cannabidiol and Vs Fenfluramine in Dravet Syndrome in the USA	10
SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study	9
SA29 Adopting Clinical Trial Best practices of Hybrid Decentralized and Risk Based Quality Management (RBQM), to Help Optimize Prospective Observational (Real-World Evidence) Studies in Compliance, Co	9
MSR58 Sentimental Analysis of Twitter Data on Screen Media Use and Screen Media Parenting in the United States	9
POSA186 Epidemiological Disease Burden of Mental and Behavioural Disorders Due to Use of Tobacco Based on Routinely Collected Health Insurance Claims Data	9
HTA59 Association Between Information Sources of Manufacturer-Proposed Utility Values and the NICE Technology Appraisal Committee's Acceptance	9
HSD42 Utilization and Cost of Molecular Diagnostics and Genetic Testing Prescribed By Various Medical Specialties in the United States	9
HSD106 Analysis of Diagnostic and Medical Delay Data Among Lung Cancer Patients in 2019 and 2020	9
MSR17 Logical Soundness in a Discrete Choice Experiment Study of Benefit Risk Preferences	9
HSD116 Bullous Pemphigoid Disease Activity and Initiation of Systemic Therapy in the Real-World Setting	9
MSR37 Methods for Recovering Missing Longitudinal Biomarker Values from Electronic Health Record Data	9
SA30 Evaluation of National Approvals and Data Collection Durations in Retrospective Noninterventional Medical Record Review Studies Conducted in the United States (US), Canada, Europe (EU), and Asia	9
HTA6 Evaluation of Ethical Aspects Associated With Health Technology: Lessons Learnt From Indian HTA Reports	9
PRS27 A Systematic Review on the Impact of Digital Health Technologies in Latent Tuberculosis Infection Management	9
EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis	9
POSC133 Use of Expert Elicitation to Extrapolate Observed Intermediate Clinical Trial Outcomes to Clinically Meaningful Long-Term Outcomes for Use in Health Technology Assessments: A Case Study in a R	9
POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting	9
HTA20 Safety and Cost Analysis of Image-Guided Functional Endoscopic Sinus Surgery in China	9
MSR12 Eliciting Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): A Non-Parametric Linear Optimization Approach	9
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment	9
PRS12 The Budgetary IMPACT of Introducing an Inactivated Influenza Vaccine for the Immunization of Adult Patients with Comorbidities, Covered By Private Insurance in Dubai	9
MSR36 Developing the Consolidated Health Outcomes/Interventions Choice-Modeling Evaluation Standards (CHOICES): A Content Analysis	9
POSC162 Cost Effectiveness Analysis of Nivolumab Plus Ipilimumab Therapy in Patients with Advanced Non-Small Cell Lung Cancer in Japan	9
MSR7 Evaluating the Impact of Weighted Sample Size on Matching Adjusted Indirect Treatment Comparisons between Trials with Time-to-Event Outcome: A Simulation Study	9
POSC152 Cost-Effectiveness Analysis of Follitropin ALFA Product (GONAL-F) Compared to Its Biosimilars Based on Meta-Analysis of Randomized Controlled Trials	9
HSD13 Emergency Department Hyperkalemia Outcomes Are Improved with Newer Potassium Binders	8
EE143 Cost-Effectiveness of Belantamab Mafodotin (BELAMAF) VS. Melphalan Flufenamide in Combination with Dexamethasone (MEL+DEX) in Heavily PRE-Treated Relapsed/Refractory Multiple Myeloma Patients: A	8
EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finlan	8
MSR35 The Importance of Accounting for Heterogeneity in Economic Analysis and Best Practices for the US Setting	8
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	8
MSR28 Applied Comparison of Indirect Covariate Balance and Residual Confounding: Propensity Score Matching Versus Cardinality Matching	8
PRS21 Quantifying the years of life lost due to COVID-19 in Colombia: preliminary estimates	8
PSS5 The Cost-Effectiveness of Dexamethasone Intravitreal Implant Versus Anti-Vascular Endothelial Growth Factor Therapies for Eyes with a Phakic Lens in UK Clinical Practice	8
MSR67 Bridging and Validation of a Thyroid Eye Disease (TED) Specific Quality of Life (QOL) Questionnaire to Utility Values Assessed By a Time Trade-Off (TTO) Analysis	8
MSR45 Smooth Algorithm: An Automatic Method to Estimate the Most Likely Drug Combination in Electronic Health Records. Development and Validation Study	8
POSC154 Cost-Effectiveness of Binocular Treatment for Amblyopia: A Markov Model Framework	8
HTA48 An Integrated Approach to HTA Assessments in the EU: Hype or Hope?	8
HTA68 Digital Health – Where Do We Stand From a Market Access Perspective in the EU-4 and the UK?	8
MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression	8
POSB174 Clinical and Economic Impact of Non-Pharmacological Interventions on the COVID-19 Pandemic: A Predictive Model Based on the Spanish Case	8
POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China	8
HSD16 Impact of Provider Nudges on Herpes Zoster Vaccine Series Completion during the COVID-19 Pandemic in the United States	8
EE111 Adoption of Piecewise Modelling: A Review of Nice Health Technology Appraisals in Oncology	8
EE135 Cost-Utility Analysis of Benralizumab in Severe Eosinophilic Asthma in Colombia	8
HSD45 Potential Patient Hub Services Opportunities in the Ex-US Drug Market: Borrowing from US Experience	8
EE185 Healthcare Resource Utilization in US Clinical Practice Among Patients with von Willebrand Disease	8
MSR54 Multi-Task Learning in Click-through-Probability (Multi-CTP) Prediction for Real-World Digital Content Recommendation	8
POSC167 A Meta-Analysis and Cost-Minimization Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy with Targeted Molecular Agents in the First-Line Treatment of Metastatic A	8
HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy	8
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany	8
EE161 Loss of Employment Duration and Productivity for Patients With Different Subtypes and Stages of Lung Cancer	7
POSC61 Cost-Effectiveness of ROS1-Testing Strategy Compared to a NO-ROS1-Testing Strategy in Advanced NSCLC in Spain	7
HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?	7
PRO50 A Discrete Choice Experiment to Derive Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France	7
HTA24 Orphan Drugs: What Is the Impact of Special Provisions in Value Assessment?	7
RWD99 The Financial Burden of DM on the Public Health System of Greece: Using Big Data From Greece	7
EE140 The Opportunity Cost of Managing Toric IOL Rotation Cases for a Private Cataract Surgery Centre in India: A Decision-Analytic Model Comparing Three Toric IOLs	7
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	7
HSD1 Treatment With Dual and Triple Therapy in Chronic Obstructive Pulmonary Disease in Line With Current Guidelines Reduces the Carbon Footprint	7
EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol	7
EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England	7
HTA32 Characteristics of Data Sources and Inputs Used in Value and Health Technology Assessment Economic Evaluations: A Pilot Analysis	7